ArticleJournal of diabetes investigation2026
Fulminant type 1 diabetes with high-titer anti-glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 61-year-old man visited our hospital with a sudden onset of polydipsia and polyuria occurring 5 days prior, accompanied by a 5-kg weight loss. A month prior, his glycated hemoglobin level was 6.2%. Precisely 8 days before the first visit, he had a fever, and hyperglycemic symptoms began shortly thereafter. At the first visit, he had a blood glucose level of 465 mg/dL, a glycated hemoglobin level of 7.7%, and ketosis. He was diagnosed with fulminant type 1 diabetes mellitus. The antiglutamic acid decarboxylase (GAD) antibodies were >2000 IU/mL, without other pancreatic islet-related autoantibodies. The human leukocyte antigen haplotype was DRB1*09:01-DQB1*03:03 and DRB1*13:02-DQB1*06:04. Intensive insulin therapy was initiated, and the patient was admitted for monitoring the blood glucose profile. The anti-GAD antibody turned negative approximately 7 months later. Some infections may have triggered rapid pancreatic islet destruction in an autoimmunity-induced impaired glucose tolerance state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.